Zealand Pharma AS (FRA:22Z)
€ 96.55 -0.4 (-0.41%) Market Cap: 6.89 Bil Enterprise Value: 5.80 Bil PE Ratio: 0 PB Ratio: 5.81 GF Score: 67/100

Zealand Pharma A/S Obesity R&D Event Transcript

Dec 05, 2023 / 01:30PM GMT
Release Date Price: €45 (+3.12%)
Anna Krassowska Zealand Pharma A;S;VP
Head of IR & Corporate Communications

/- -

So I wanted to welcome everyone, and thank you for joining us today here in London and everyone who's also joining us online. I'm Anna Krassowska, I'm Head of Investor Relations and Communications at Zealand Pharma, and we are very excited to be here today to discuss the future of obesity management. How we believe the mechanisms that we are pursuing and in particular the peptides that we are developed, they shape a future treatment of obesity.

So please be aware, therefore, that we will be making forward-looking statements today that carry risks and uncertainties and actual results may differ from these forward-looking statements.

So for the agenda today, we will start by framing the global obesity pandemic that we are facing today. And then this will be followed by three presentations that cover the scientific mechanisms and the clinical potential of the candidates in our pipeline.

So first, we'll start with our two wholly-owned candidates, our GLP-1, GLP-2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot